Targeted Nanoparticle PET / CT Imaging of Chemokine Receptor CCR 5 in Vascular Injury Model Using

Published online: March 3, 2014. 2014;55:629-634. J Nucl Med. Gropler, Craig J. Hawker and Yongjian Liu Hannah P. Luehmann, Eric D. Pressly, Lisa Detering, Cynthia Wang, Richard Pierce, Pamela K. Woodard, Robert J. Targeted Nanoparticle PET/CT Imaging of Chemokine Receptor CCR5 in Vascular Injury Model Using http://jnm.snmjournals.org/content/55/4/629 This article and updated information are available at: http://jnm.snmjournals.org/site/subscriptions/online.xhtml Information about subscriptions to JNM can be found at: http://jnm.snmjournals.org/site/misc/permission.xhtml Information about reproducing figures, tables, or other portions of this article can be found online at:

[1]  Sameer Bansilal,et al.  Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations , 2008, Journal of Nuclear Medicine.

[2]  Vasilis Ntziachristos,et al.  Inflammation in Atherosclerosis: Visualizing Matrix Metalloproteinase Action in Macrophages In Vivo , 2006, Circulation.

[3]  C. Weber,et al.  Atherosclerosis: current pathogenesis and therapeutic options , 2011, Nature Medicine.

[4]  R. Koenen,et al.  Therapeutic targeting of chemokine interactions in atherosclerosis , 2010, Nature Reviews Drug Discovery.

[5]  Robin P Choudhury,et al.  Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[6]  C. Pert,et al.  Chemokine receptor 5 antagonist d-Ala-peptide T-amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer's disease , 2005, Neuroscience.

[7]  A. Zernecke,et al.  Chemokines in the vascular inflammatory response of atherosclerosis. , 2010, Cardiovascular research.

[8]  R. Pierce,et al.  PET Imaging of Chemokine Receptors in Vascular Injury–Accelerated Atherosclerosis , 2013, The Journal of Nuclear Medicine.

[9]  C. Pert,et al.  Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. , 2003, Current HIV research.

[10]  C. Reutelingsperger,et al.  P-Selectin Imaging in Cardiovascular Disease: What You See Is What You Get? , 2011, The Journal of Nuclear Medicine.

[11]  Paul M Ridker,et al.  Inflammation in atherosclerosis: from pathophysiology to practice. , 2009, Journal of the American College of Cardiology.

[12]  P. Strange,et al.  Pathways for internalization and recycling of the chemokine receptor CCR5. , 2002, Blood.

[13]  Eric D. Pressly,et al.  Targeting Angiogenesis Using a C-Type Atrial Natriuretic Factor–Conjugated Nanoprobe and PET , 2011, The Journal of Nuclear Medicine.

[14]  Eric D. Pressly,et al.  Structural effects on the biodistribution and positron emission tomography (PET) imaging of well-defined (64)Cu-labeled nanoparticles comprised of amphiphilic block graft copolymers. , 2007, Biomacromolecules.

[15]  P. Libby,et al.  Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. , 2012, Circulation research.

[16]  R. Westrick,et al.  Murine models of vascular thrombosis (Eitzman series). , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[17]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[18]  D. Greaves,et al.  The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics , 2004, Current opinion in lipidology.

[19]  J. Maguire,et al.  Chemokine receptor CCR5: from AIDS to atherosclerosis , 2011, British journal of pharmacology.

[20]  C. Pert,et al.  Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA). , 2005, Antiviral research.

[21]  Christian Weber,et al.  Chemokines in Atherosclerosis , Thrombosis , and Vascular Biology Series Editor : Christian Weber Chemokines in Atherosclerosis An Update , 2008 .

[22]  Craig J Hawker,et al.  Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer. , 2013, Bioconjugate chemistry.

[23]  François Mach,et al.  Inflammation and Atherosclerosis , 2004, Herz.

[24]  Fabien Hyafil,et al.  Inflammation Imaging in Atherosclerosis , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[25]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[26]  Michael J Welch,et al.  Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications. , 2012, Bioconjugate chemistry.

[27]  A. Zernecke,et al.  Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. , 2006, Blood.

[28]  P. Perret,et al.  In Vivo Molecular Imaging of Atherosclerotic Lesions in ApoE-/-mice using VCAM-1-Specific , 99 m Tc-Labeled Peptidic Sequences , 2013 .

[29]  M. Chiariello,et al.  Molecular imaging of atherosclerosis in translational medicine , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  W. Kuziel,et al.  CC chemokine receptor 5 influences late-stage atherosclerosis. , 2007, Atherosclerosis.

[31]  Ralph Weissleder,et al.  The Vascular Biology of Atherosclerosis and Imaging Targets , 2010, Journal of Nuclear Medicine.

[32]  D. Greaves,et al.  CC Chemokine Receptors and Chronic Inflammation—Therapeutic Opportunities and Pharmacological Challenges , 2013, Pharmacological Reviews.

[33]  F. Tacke,et al.  Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. , 2007, The Journal of clinical investigation.